[1] Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alpha immunoconjugates in the management of micrometastatic cancer[J]. J Australia Radiol, 1999, 43: 480-486.
[2] McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha emitting nuclides[J]. Eur J Nucl Med, 1998, 25: 1341-1351.
[3] Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195(anti-CD33) in patients with leukemia[J]. J Nucl Med, 1999, 40: 1935-1946.
[4] Couturier O, Faivre C A, Filippovich IV, et al. Validation of 213Bi alpha radioimmunotherapy for multiple myeloma[J].Clin Cancer Res, 1999, 5: 3165s-3170s.
[5] Palm S, BackT, Claesson I, et al. Effects of the alpha particle emitter At-211 and low dose rate gamma radiation on the human cell line Colo-205 as studies with a growth assay[J]. Anticancer Res, 1998, 18: 1671-1676.
[6] Gautherot E, Rouvier E, Danel L, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I labeled bivalent hapten[J]. J Nucl Med, 2000, 41: 480-487.
[7] Wisernan GA, Write CA, Stabin M, et al. Phase Ⅰ/Ⅱ 90Y-zevalin radioimmunotherapy dosimetry result in relapsed or refractory non-Hodgkin's lymphoma[J]. Eur J Nuel Med,2000, 27: 766-777.
[8] O'Donnell RT, Shen S, Denardo SJ, et al. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma[J]. Anticancer Res, 2000, 20: 3647-3655.
[9] Kinuya S, Yokoyama K, Kawashima A, et al. Radioimmunotherapy with 186Re-labeled mono-clonal antibody to treat liver metastases of colon cancer cells in nude mice[J].Cancer Biother Radiopharm, 2002, 17: 681-687.
[10] Lou C, Chen ZN, Bian HJ, et al. Pharmacokinetics of radioimmunotherapeulic agent of direct labeling mAb 188Re-HAb18[J]. World J Gastroenterol, 2002, 8: 69-73.
[11] Iznaga-Escobar N. Direct radiolabeling of mon-oclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors-a review of radiolabeling characteristics,quality control and in vitro stability studies[J]. Appl Radiat Isot,2001, 54: 399-406.
[12] Gestin JF, Loussouarn A, Bardies M, et al. Two step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re labeled bivalent hapten: biodistribution and dosimetry studies[J]. J Nucl Med, 2001, 42: 146-153.
[13] Denardo GL, Denardo SJ, Donnell RT, et al. Are Radiometal labeled antibodies better than iodine-131-1abeled antibodies: comparative pharmacokinetics and dosimetry of copper 67, iodine 131 and yttrium 90 labeled lyre-1 antibody in patients with non-Hodgkin's lymphoma[J]. Clin Lymphoma,2000, 1: 118-126.
[14] Neves M, Kling A, Lambrecht RM. Radionuclide production for therapeutic radiopharmaceuticalsp[J]. Appl Radiat Isot,2002, 57: 657-664.
[15] Ward RL, Packham D, Smythe AM, et al. Phase I clinical trial of the chimeric monoclonal antibldy (c30.6) in patients with metastatic colorectal cancer[J]. Clin Cancer Res, 2000,6: 4674-4683.
[16] Chrastina A, Pastorekova S, Pastored J. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody[J]. Neoplasma, 2003, 50: 13-21.